MedTrace Logo

Sitagliptin Mechanism of Action Study in Patients With Type 2 Diabetes Mellitus (0431-059)

NCT00704132 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2017-05-12

Study results available
· View outcomes & findings →

Summary

A clinical study to determine the safety, efficacy and the way sitagliptin works in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

Comparator: sitagliptin phosphate

Sitagliptin tablet 100 mg, administered once daily before the morning meal.

DRUG

Comparator: placebo (unspecified)

Matching placebo tablet, administered once daily before the morning meal.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-14
Primary Completion
2010-04-28
Completion
2010-04-28

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704132 on ClinicalTrials.gov